ARYx Therapeutics, Inc.

A four-years-delayed Phase III clinical trial for the oral anticoagulant (OAC) tecarfarin is back on track now that Menlo Park, California-based Armetheon has raised a $7m Series A venture capital rou

Serotonin (5-HT) receptor 4 agonists in development for gastrointestinal motility disorders may be destined for an easier approval path than diabetes and obesity treatments when it comes to cardiovasc

Call it the linaclotide bump. Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome (IBS) hope to take advantage of a resurg

Dedicated cardiovascular safety studies should not be required for serotonin (5-HT) receptor 4 agonists being developed for gastrointestinal motility diseases, but Phase III studies should enroll pati